Review demonstrates multi-target anti-androgenic mechanisms of dietary plant extracts across androgen-driven disorders, highlighting therapeutic potential of synergistic bioactive compounds.
Androgen dysregulation impairs the homeostasis of the prostate, hair follicles, and ovaries, driving the pathogenesis of prostate cancer (PCa), benign prostatic hyperplasia (BPH), androgenetic alopecia (AGA), and polycystic ovary syndrome (PCOS). Current antiandrogen therapies are constrained by drug resistance, off-target toxicity, and limited long-term efficacy. Plant extracts, enriched with bioactive constituents such as polyphenols, alkaloids, and flavonoids, represent promising multi-target candidates. Therefore, focusing on plant extracts—particularly those of dietary origin—this review summarized the mechanisms by which they regulate androgen-dependent and androgen-independent signaling pathways, and recent advances in nutritional interventions targeting androgen-responsive organs. Furthermore, it discussed the multi-component combined effects and factors affecting in vivo exposure of plant extracts, including metabolic transformation and tissue distribution, which may influence the anti-androgenic activity. In summary, anti-androgenic plant extracts primarily target androgen synthesis and AR signaling across various androgen disorder models, with crosstalk into cell growth and cycle, anti-inflammatory pathways, and regulation of growth factors. This multi-target regulation relies on the mixture effects of plant extracts. Future research should focus on three directions: extract standardization, clinical validation, and advanced delivery systems.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: